Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1/2IIT Standard Optimization of Autologous Stem Cells by Intranasal and Intravenous Administration to Treat Parkinson's Disease and Atypical Parkinsonism
The purpose of this study is to measure outcomes using intranasal and intravenous autologous bone marrow mesenchymal stem cells (BM-MSCs) for Parkinson Disease (PD) and Parkinson's Plus (PPS) patients.
100 Clinical Results associated with Apeiron Research Center
0 Patents (Medical) associated with Apeiron Research Center
100 Deals associated with Apeiron Research Center
100 Translational Medicine associated with Apeiron Research Center